A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual ...

Encouraging anti-tumour activity seen across all dose levels and in various tumour indications Clinical benefit rate of 80% for 10 patients with HER2+ oesophageal cancer who had received prior therapy ...

Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespect ...

Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of AGMB-447 in healthy participants -- ...

Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...

Clinical study updateUPPSALA, Sweden, Jan. 9, 2026 /PRNewswire/ -- Synartro is advancing the candidate drug SYN321, a novel intra-articular treatment for knee osteoarthritis, through a phase ...

In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonst ...

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) -Clinical data to date supports a potentially ...

Addex spin-out Neurosterix begins phase 1 study with M4 PAM - NTX-253 for schizophrenia: Geneva, Switzerland Thursday, January 8, 2026, 12:00 Hrs [IST] Addex Therapeutics, a clini ...

Study: Dual impacts of serine/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation. Image Credit: Lightspring/Shutterstock ...